Weight-loss drugs have dominated the pharmaceutical market with their rapid success. Barclays head of European pharmaceuticals research, Emily Field, joins Seana Smith and Brad Smith on Morning Brief to discuss her outlook for the GLP-1 market in 2025:
“In terms of the inflection point for the market, you know, both Novo Nordisk (NVO) and Eli Lilly (LLY) have clinical catalysts that are scheduled throughout the year. But really, I think what is going to be important in terms of driving revenue upside and the impact sector-wide is just the prescription data … [as] both companies have been investing billions in capacity expansion such that we think that we’re probably going to really start to see the benefits of that here in 2025.”
Watch the video above for more about the analyst’s expectations for the weight-loss drug space.
To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.
This post was written by Naomi Buchanan.
